Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT01242072
Official study title

Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies

Study summary

This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin are normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II study using the 3 agents combined will begin.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedpalifosfamide-tris

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 29, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Alaunos Therapeutics

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Alaunos Therapeutics
Interventions being studied
Drug: palifosfamide-tris
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • 18 years old or greater
  • Malignancy scheduled to receive etoposide and carboplatin therapy
  • Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1
  • Adequate bone marrow, liver, renal function and coagulation status
  • Informed consent
  • Agree to use birth control through 28 days of last treatment dose
  • Pregnancy test for women of child-bearing potential
  • No available standard therapy
Reasons someone may not be able to joinExclusion criteria
  • Allergy to the the study treatment drugs
  • Unstable current medical condition
  • Presence or history of injury to the urinary tract
  • Active infection
  • Major surgery within 4 weeks prior to treatment
  • Minor surgery within 2 weeks prior to treatment
  • Current acute steroid therapy or taper
  • Currently pregnant or nursing
  • Substance abuse or condition that may interfere with participation
  • Received other investigational drugs within 30 days
  • Within 4 weeks of their last chemotherapy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Indiana University Simon Cancer CenterIndianapolis, Indiana
  • Horizon Oncology ResearchLafayette, Indiana
  • Medical Consultants, PCMuncie, Indiana
  • Washington UniversitySt Louis, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 29, 2026. Always confirm current availability with the study team.

View original record ↗